Back to Search
Start Over
Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.
- Source :
-
Leukemia & Lymphoma . Jan2018, Vol. 59 Issue 1, p233-236. 4p. - Publication Year :
- 2018
-
Abstract
- The article presents a case study of a reaction to the dasatinib drug in a 49-year-old man with chronic myeloid leukemia (CML) harboring a e8a2 BCR-ABL1 transcript gene with a somatic mutation of TP53BP2 and cadherin-10 (CDH10) gene. The patient was diagnosed with CML harboring the e8a2 transcript, and his variant BCR-ABL1:ABL1 ratio was revealed. He obtained complete remission at the molecular and hematological level.
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 59
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 125435364
- Full Text :
- https://doi.org/10.1080/10428194.2017.1323269